CDMO to process Japanese company’s cancer fighter, darinaparsin.
Alcami announced on November 9th, that it has finalized manufacturing and quality agreements with Solasia Pharma K.K. for the clinical supply and manufacture of the company’s active pharmaceutical ingredient (API) darinaparsin, characterized as a novel mitochondrial-targeted agent developed for the treatment of an array of hematological and solid cancers.
Based in Japan, Solasia is a specialty pharma company focused on developing innovative oncology medications. In 2011, Solasia acquired rights to darinaparsin from ZIOPHARM Oncology. The acquisition of darinaparsin provided Solasia with a high-potential candidate for the treatment of peripheral T-cell lymphoma (PTCL), which is currently in Phase II pivotal trials in Asia.
Yoshihiro Arai, President and CEO of Solasia said: "We are pleased to entrust Alcami with this project. Finding a responsible partner for the development and manufacturing of our API was a significant step in our clinical program." According to Alcami, darinaparsin process development and clinical manufacturing will begin in before the end of the year and commence in Alcami’s new highly potent API Center of Excellence in Germantown, Wisconsin.
"We are extremely grateful for the opportunity to partner with Solasia as the trusted supplier of darinaparsin. Our relationship is an excellent example of Alcami's dedication to delivering reliable and high quality medicines across the globe. As we continue to grow our established business in Japan, we look forward to supporting Solasia for its future clinical and commercial success," explained Syed T. Husain, Chief Commercial Officer of Alcami.
